Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. van Bragt (Amsterdam, Netherlands), I. Adcock (London, United Kingdom), G. Anderson (Melbourne, Australia), E. Bel (Amsterdam, Netherlands), G. Braunstahl (Rotterdam, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), J. Busby (Belfast, United Kingdom), G. Canonica (Milan, Italy), H. Cao (East Hanover, NJ, United States of America), K. Chung (London, United Kingdom), Z. Csoma (Budapest, Hungary), D. Davies (Southampton, United Kingdom), B. Dahlen (Huddinge, Sweden), R. Djukanovic (Southampton, United Kingdom), C. Genton (Lausanne, Switzerland), T. Gibson-Latimer (Sheffield, United Kingdom), D. Hamerlijnck (Sheffield, United Kingdom), L. Heaney (Belfast, United Kingdom), E. Heuvelin (Lausanne, Switzerland), I. Horvath (Budapest, Hungary), S. Korn (Mainz, Germany), M. Kots (Parma, Italy), P. Kuna (Lodz, Poland), N. Kwon (Brentford, United Kingdom), R. Louis (Liege, Belgium), R. Naddaf (Amsterdam, Netherlands), V. Plaza (Barcelona, Spain), D. Ramos Barbon (Barcelona, Spain), L. Richards (Amsterdam, Netherlands), S. Skrgat (Golnik, Slovenia), E. Weersink (Amsterdam, Netherlands), V. Yasinska (Huddinge, Sweden), S. Wagers (Maasmechelen, Belgium), A. Maitland-Van Der Zee (Amsterdam, Netherlands). Characteristics and treatment regimens across ERS SHARP severe asthma registries. 5354

Member's Comments

No comment yet.

Related content which might interest you: Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 COPD therapy based on clinical phenotypes: Baseline data from the Czech multicentre research database of COPD Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Patients’ adherence to chronic treatment in lung diseases: Preliminary data from a randomized controlled trial Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Prescribing patterns for UK patients commencing first maintenance therapy for COPD Source: International Congress 2014 – COPD markers Year: 2014 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Effect of COPD medications on exacerbation rates in a real-life COPD patient cohort - data from the Czech Multicenter Research Database of COPD. Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Treatment and recovery of symptom-based exacerbations in the INSPIRE study Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Greatest International ANti-infective Trial (GIANT) – the German cohort: moxifloxacin treatment provides short- and long-term benefits in AECB patients Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006 Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Predictors of long-term mortality after hospitalization for COPD; A Scandinavian multicentre study Source: International Congress 2014 – Longitudinal studies of respiratory disease Year: 2014 Proportion of complete responders after one year of treatment with biologics for severe asthma - Results from the nationwide Danish Severe Asthma Register. Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020 Impact of the GOLD 2011 guidelines on treatment regimens in COPD patients Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015